Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the
Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the radiopharmaceuticalsdivision of Du Pont Merck Pharmaceutical. He also held positionsat American Hospital Supply, where he developed an understandingof the injectable drug market, which will be key to marketingSonus' agents, according to the company.
Sonus, of Costa Mesa, CA, is developing intravenous ultrasoundcontrast agents based on a dodecafluoropentane-based emulsion.The company has filed an investigational new drug (IND) applicationwith the Food and Drug Administration for EchoGen, a cardiac contrastagent (SCAN 1/19/94).